ABSTRACT
Many systematic reviews and meta-analyses have been conducted in the field of Intimate Partner Violence (IPV) and the evidence shows small to moderate effect sizes in improving mental health. However, there is considerable heterogeneity due to great variation in participants, interventions and contexts. It is therefore important to establish which participant and intervention characteristics affect the different psychosocial outcomes in different contexts. Individual Participant Network Meta-analysis (IPDNMA) is a gold-standard method to estimate the effects with the highest precision possible and estimate moderating effects, compare the effectiveness of the different interventions and thus answer the question of which intervention is best-suited for whom. We will conduct an IPDNMA of randomised controlled trials (RCTs) of psychosocial interventions for IPV survivors aimed at improving mental health, well-being, risk-lowering and intervention acceptability outcomes compared to any type of control (PROSPERO registration number: CRD42023488502). We aim to establish a collaboration with the authors of the eligible RCT, to obtain and to harmonise the Individual Participant Data of the trials, and conduct an one-stage IPDNMA will be conducted under a Bayesian framework using the multinma package in R, after testing which characteristics of the participants and interventions are effect modifiers. There are however inherent limitations of IPDMAs, such as depending on data availability and missing nuancing through the harmonisation of variables. We aim to address these possibly by creating pseudo-IPD and sensitivity analyses. This approach is novel in the field and it can inform more efficient clinical and policy-related decision making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded through Christina Palantza's postgraduate research stipend from the University of Bristol
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript reports the protocol for secondary research using individual participant data from randomised controlled trials that have published their findings. Ethics approval is not required for secondary research. The primary trials all had ethics approval from the relevant national or institutional bodies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
It will not be possible to share the data publicly upon completion of the study, because they belong to the authors that conducted the eligible studies, and they will share them with us only for the analysis of this study.
https://osf.io/72uwe/?view_only=1ba290a378514c3a929d7eac035bfd67
